

Substitute for form 1449B/PTO

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
IN AN APPLICATION**
**LISTING OF REFERENCES**
**February 5, 2008**

(Use several sheets if necessary)

**ATTORNEY DOCKET NO.**  
3506.1000-002

**APPLICATION NO.**  
10/757,364

**FIRST NAMED INVENTOR**  
Steven B. Landau

**FILING DATE**  
January 13, 2004

**EXAMINER**  
Yong Soo Chong

**CONFIRMATION NO.**  
3343

**GROUP**  
1617

**U.S. PATENT DOCUMENTS**

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AC7	6,194,382	02-27-2001	Crain, <i>et al.</i>

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AX5	Wu, Y., <i>et al.</i> , "Effects of Acute and Chronic Administration of MCI-225, a New Selective Noradrenaline Reuptake Inhibitor with 5-HT <sub>3</sub> Receptor Blocking Action, on Extracellular Noradrenaline Levels in the Hypothalamus of Stressed Rats," <i>Jpn J of Pharmacology</i> , 83, pp. 31-38 (2000).
AY5	Ishigooka, Jr., <i>et al.</i> , "Serotonin-Noradrenaline Reuptake Inhibitors(SNRIs)," <i>Nippon Rinsho</i> , 59, pp. 1523-9, (2001) - Abstract Only.
AZ5	Spiller, R., "Pharmacotherapy: Non-Serotonergic Mechanisms," <i>Gut</i> , 51, Suppl, i87-i90 (2002).

EXAMINER

/Yong Chong/

DATE CONSIDERED

03/11/2008

784516\_1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./